Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENN0403 for AKI Prevention in Cardiac Surgery
NCT06632613Phase 2Recruiting
- Sponsor
- EnnovaBio
- Start
- Nov 2024
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ENN0403 in acute kidney injury (AKI) (3 arms), sponsored by EnnovaBio. Primary endpoints: Incidence of adverse events (AE) and serious adverse events (SAE) at 30 days and Percentage of subjects developing AKI in different AKI stages based on Serum Creatinine and/or Urine Output per KDIGO definition at 5 days. Started Nov 2024; status: recruiting.
02
Drugs
ENN0403
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT06632613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06632613.